Why a vigorous LV can still fail to deliver flow

A small, vigorously contracting left ventricle can coexist with poor forward flow. Dynamic left ventricular outflow tract obstruction (LVOTO) is one possible explanation. Reduced filling, low vascular resistance and adrenergic stimulation can bring susceptible mitral tissue into the outflow tract during systole. Increasing contractility may then worsen the obstruction. Confirm the mechanism with echocardiography and Doppler before changing shock treatment.

Case Snapshot

• A 69-year-old man with urosepsis had a PEA arrest and was resuscitated.
• Norepinephrine was started; hypotension persisted despite escalation.
• POCUS showed a small, hyperdynamic LV without RV strain; lung ultrasound showed bilateral B-lines.
• The original account reports improved blood pressure and resolution of obstruction after fluids.

The snapshot does not provide the Doppler tracing, gradient, mitral-regurgitation assessment or fluid volume. These findings raise suspicion, but a fluid response alone does not prove LVOTO. B-lines also require an explanation and do not establish that additional fluid is safe.

Connect the anatomy to the shock physiology

In SAM-mediated obstruction, systolic anterior motion of the mitral leaflet brings it toward the septum, narrowing the LV outflow tract. Disturbed leaflet coaptation can also cause mitral regurgitation (MR), reducing forward stroke volume and raising left-atrial pressure. Pulmonary edema can therefore coexist with a small LV cavity. A high ejection fraction describes the fraction ejected, not the adequacy of systemic flow.

Low preload makes the cavity smaller. Low afterload and increased contractility encourage rapid emptying; tachycardia shortens filling time. Together they may amplify obstruction. Septal geometry and mitral or papillary-muscle abnormalities increase susceptibility, but dynamic obstruction during sepsis or catecholamine exposure does not establish hypertrophic cardiomyopathy (HCM).

LVOTO may contribute to mixed shock alongside vasoplegia, hypovolemia, post-arrest myocardial dysfunction or other disease. A small LV alone cannot distinguish these mechanisms. Do not assume that every hypotensive patient needs more inotropy, or that every patient with obstruction can safely lose all adrenergic support.

When to look for it

Look for dynamic obstruction when hypotension persists with a small hyperdynamic LV, especially if greater adrenergic stimulation is followed by worse perfusion. These are clues, not diagnostic criteria. Continue assessing competing causes, including bleeding, vasoplegia, myocardial ischemia or dysfunction, RV failure, tamponade and pulmonary embolism. Absence of RV strain does not exclude PE.

Confirm the obstruction, not just the appearance

• Identify SAM and the site of narrowing on 2-D imaging; use color and pulsed-wave Doppler to localize acceleration. Distinguish LVOT obstruction from mid-cavity obliteration and aortic-valve stenosis.
• Align continuous-wave Doppler with LVOT flow. A late-peaking, dagger-shaped envelope supports dynamic obstruction. MR can contaminate the signal: check the jet direction, timing and alignment rather than tracing the highest velocity.
• A peak instantaneous gradient ≥30 mmHg is the conventional HCM obstruction threshold. It is not a stand-alone threshold for shock treatment; interpret the gradient with loading conditions, forward flow and perfusion.
• Assess MR, LV and RV function and lung congestion. If image quality or Doppler interpretation is uncertain, obtain expert echocardiography; an incomplete scan cannot settle the mechanism.

These acquisition principles are described in the BSE HCM echocardiography guideline. In an unstable patient, document current conditions and serial response; elective HCM provocation maneuvers are not a resuscitation step. The 2024 HCM guidance applies to HCM and should not be transferred wholesale to septic shock. External SAM demonstration (YouTube).

Treat the dominant mechanism and reassess

Correct underfilling only when more preload is likely to help and is tolerable. A passive leg raise with a reliable forward-flow measurement can inform the decision. If a small fluid challenge is appropriate, reassess immediately. Stop further loading when flow does not improve or oxygenation and congestion worsen. Bilateral B-lines or severe MR make tolerance particularly important; a positive responsiveness test is not permission for unlimited fluid.

Maintain perfusion while reducing aggravating factors. Avoid reflex escalation of beta-adrenergic inotropy when confirmed obstruction is worsening. Vasodilators or excessive diuresis may aggravate underfilling or low afterload; genuine congestion can still require cautious decongestion. An intra-aortic balloon pump may aggravate obstruction through afterload reduction, as case reports illustrate; mechanical-support decisions need expert assessment of the actual mechanism.

Choose vasopressors in context. Norepinephrine remains first-line support for most septic shock. Its vascular effects can help pressure and filling, while its beta-adrenergic activity may aggravate obstruction in susceptible patients. Do not stop it abruptly. In selected confirmed LVOTO, phenylephrine or adjunctive vasopressin may support vascular tone while limiting beta stimulation. The HCM recommendation for phenylephrine in fluid-unresponsive acute hypotension is not evidence for routine phenylephrine in sepsis. Follow pressure and forward flow; a higher pressure can coexist with lower output.

Beta-blockade is a specialist, monitored decision. Reducing excessive contraction and heart rate can relieve confirmed obstruction, but can also cause bradycardia, hypotension or loss of cardiac output. An expert-led short-acting agent such as esmolol may be considered when obstruction is a major driver and perfusion can be closely supported and reassessed. Evidence for this rescue approach in septic LVOTO includes case reports, not a validated protocol. It is not empirical treatment for a small LV, unexplained hypotension or septic shock. The 2026 Surviving Sepsis Campaign suggests against beta-blockers as treatment for septic shock itself; a proven obstructive mechanism is a separate clinical question.

After each intervention, reassess blood pressure, rhythm, capillary refill and organ perfusion alongside forward flow, SAM, LVOT gradient, MR and pulmonary congestion. A lower gradient is not enough if cardiac output has fallen. Continue treatment of the underlying illness, including infection and source control where indicated, and involve critical-care/cardiology expertise for persistent instability.

What the evidence supports

Chauvet et al. (2015) observed dynamic intraventricular obstruction in 47 of 218 patients with septic shock; many improved their stroke index after fluid. This was an observational, broader intraventricular-obstruction phenotype, not proof that all septic LVOTO requires fluids or that fluid improves survival.

Balik et al. (2020) described 10 severely affected patients among 527 screened: SAM, severe MR and pulmonary edema were present. Adding vasopressin was associated with lower norepinephrine requirements and LVOT gradients and improved oxygenation. This small uncontrolled series supports physiological plausibility, not superiority or a survival benefit. No universal fluid, pressor or beta-blocker recipe follows from either study.

Clinical takeaway

In shock with a small hyperdynamic LV, consider dynamic obstruction and confirm it. Treat loading conditions, contractility and coexisting shock together. The useful endpoint is improved perfusion without worsening congestion, not simply a more reassuring Doppler number.

Selected references

• 2024 AHA/ACC multisociety HCM guideline: official slide set. HCM-specific obstruction thresholds and treatment recommendations.
• BSE practical guideline for echocardiography in adult HCM (2021). Doppler localization and MR/LVOT discrimination.
• Chauvet et al. Early dynamic left intraventricular obstruction in septic shock (2015). Observational cohort.
• Balik et al. Vasopressin in septic shock with dynamic LVOTO (2020). Small uncontrolled series.
• Surviving Sepsis Campaign adult guidelines (2026). Current sepsis management; not a dedicated LVOTO protocol.
• Patel et al. Mitral and papillary-muscle abnormalities in obstructive HCM (2015). Context for the separate published figure above.